Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer
Background: Prostate-specific antigen (PSA) is used for diagnosing prostate cancer, but does not reflect the characteristics of prostate cancer cells to allow assessment of cancer progression. PSA mRNA and circulating tumor cells (CTCs) could be potential biomarkers. However, the relationship betwee...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Prostate International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888222000022 |
| _version_ | 1827838394177159168 |
|---|---|
| author | Hyungseok Cho Cheol Kyu Oh Jiwon Cha Jae Il Chung Seok-Soo Byun Sung Kyu Hong Jae-Seung Chung Ki-Ho Han |
| author_facet | Hyungseok Cho Cheol Kyu Oh Jiwon Cha Jae Il Chung Seok-Soo Byun Sung Kyu Hong Jae-Seung Chung Ki-Ho Han |
| author_sort | Hyungseok Cho |
| collection | DOAJ |
| description | Background: Prostate-specific antigen (PSA) is used for diagnosing prostate cancer, but does not reflect the characteristics of prostate cancer cells to allow assessment of cancer progression. PSA mRNA and circulating tumor cells (CTCs) could be potential biomarkers. However, the relationship between serum PSA levels and PSA mRNA in CTCs is unclear, and this study aimed to investigate this relationship. Methods: Healthy donors (HD, n = 9), and patients with local non-metastatic stage prostate cancer (n = 30), metastatic hormone–sensitive prostate cancer (mHSPC, n = 10), and metastatic castration–resistant prostate cancer (mCRPC, n = 75), were included. The expression of PSA mRNA in CTCs was measured by droplet digital PCR. Serum PSA (ng/mL) levels and PSA mRNA (copies/μL) in CTCs were then compared using Spearman correlation coefficients. Results: PSA mRNA expression in CTCs was observed in 30% (9/30) of patients with localized cancer, 60.0% (6/10) among patients with mHSPC, 65.3% (49/75) among patients with mCRPC, and 0% among patients with HD, indicating that the detection rate of PSA mRNA increased with cancer stage. PSA mRNA expression in CTCs also increased from localized to metastatic stages. PSA mRNA levels rapidly increased in the mHSPC and mCRPC stages. Interestingly, PSA mRNA expression in CTCs was not correlated with serum PSA levels at the localized stage (R = 0.064, P = 0.512). However, there were significant correlations between serum PSA levels and PSA mRNA expression in mHSPC (R = 0.532, P = 0.041) and mCRPC (R = 0.566, P = 0.025). The number of CTCs isolated from mHSPC and mCRPC was not proportional to serum PSA and PSA mRNA levels. Conclusion: CTC PSA mRNA has the potential to be used as a biomarker to complement serum PSA protein analysis or replace serum PSA in metastatic stages of prostate cancer. |
| first_indexed | 2024-03-12T07:05:16Z |
| format | Article |
| id | doaj.art-8dac012fb29e4a6b8c060d3a007a1961 |
| institution | Directory Open Access Journal |
| issn | 2287-8882 |
| language | English |
| last_indexed | 2024-03-12T07:05:16Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Prostate International |
| spelling | doaj.art-8dac012fb29e4a6b8c060d3a007a19612023-09-02T23:31:05ZengElsevierProstate International2287-88822022-03-011011420Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancerHyungseok Cho0Cheol Kyu Oh1Jiwon Cha2Jae Il Chung3Seok-Soo Byun4Sung Kyu Hong5Jae-Seung Chung6Ki-Ho Han7Department of Nanoscience and Engineering Center for Nano Manufacturing, Inje University, KoreaDepartment of Urology, Haeundae Paik Hospital, Inje University, KoreaDepartment of Nanoscience and Engineering Center for Nano Manufacturing, Inje University, KoreaDepartment of Urology, Busan Paik Hospital, Inje University, KoreaDepartment of Urology, Bundang Hospital, Seoul National University, KoreaDepartment of Urology, Bundang Hospital, Seoul National University, KoreaDepartment of Urology, Haeundae Paik Hospital, Inje University, Korea; Corresponding author. Department of Urology, Haeundae Paik Hospital, Inje University, 875, Haeun-daero, Haeundae-gu, Busan, 48108, Korea.Department of Nanoscience and Engineering Center for Nano Manufacturing, Inje University, Korea; Corresponding author. Department of Nanoscience and Engineering, Inje University, 197, Inje-Ro, Gimhae, Gyongnam, 50834, Korea.Background: Prostate-specific antigen (PSA) is used for diagnosing prostate cancer, but does not reflect the characteristics of prostate cancer cells to allow assessment of cancer progression. PSA mRNA and circulating tumor cells (CTCs) could be potential biomarkers. However, the relationship between serum PSA levels and PSA mRNA in CTCs is unclear, and this study aimed to investigate this relationship. Methods: Healthy donors (HD, n = 9), and patients with local non-metastatic stage prostate cancer (n = 30), metastatic hormone–sensitive prostate cancer (mHSPC, n = 10), and metastatic castration–resistant prostate cancer (mCRPC, n = 75), were included. The expression of PSA mRNA in CTCs was measured by droplet digital PCR. Serum PSA (ng/mL) levels and PSA mRNA (copies/μL) in CTCs were then compared using Spearman correlation coefficients. Results: PSA mRNA expression in CTCs was observed in 30% (9/30) of patients with localized cancer, 60.0% (6/10) among patients with mHSPC, 65.3% (49/75) among patients with mCRPC, and 0% among patients with HD, indicating that the detection rate of PSA mRNA increased with cancer stage. PSA mRNA expression in CTCs also increased from localized to metastatic stages. PSA mRNA levels rapidly increased in the mHSPC and mCRPC stages. Interestingly, PSA mRNA expression in CTCs was not correlated with serum PSA levels at the localized stage (R = 0.064, P = 0.512). However, there were significant correlations between serum PSA levels and PSA mRNA expression in mHSPC (R = 0.532, P = 0.041) and mCRPC (R = 0.566, P = 0.025). The number of CTCs isolated from mHSPC and mCRPC was not proportional to serum PSA and PSA mRNA levels. Conclusion: CTC PSA mRNA has the potential to be used as a biomarker to complement serum PSA protein analysis or replace serum PSA in metastatic stages of prostate cancer.http://www.sciencedirect.com/science/article/pii/S2287888222000022BiomarkerCirculating tumor cellsProstate cancerProstate-specific antigen |
| spellingShingle | Hyungseok Cho Cheol Kyu Oh Jiwon Cha Jae Il Chung Seok-Soo Byun Sung Kyu Hong Jae-Seung Chung Ki-Ho Han Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer Prostate International Biomarker Circulating tumor cells Prostate cancer Prostate-specific antigen |
| title | Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer |
| title_full | Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer |
| title_fullStr | Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer |
| title_full_unstemmed | Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer |
| title_short | Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer |
| title_sort | association of serum prostate specific antigen psa level and circulating tumor cell based psa mrna in prostate cancer |
| topic | Biomarker Circulating tumor cells Prostate cancer Prostate-specific antigen |
| url | http://www.sciencedirect.com/science/article/pii/S2287888222000022 |
| work_keys_str_mv | AT hyungseokcho associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT cheolkyuoh associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT jiwoncha associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT jaeilchung associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT seoksoobyun associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT sungkyuhong associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT jaeseungchung associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer AT kihohan associationofserumprostatespecificantigenpsalevelandcirculatingtumorcellbasedpsamrnainprostatecancer |